- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Sickle-cell Anemia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Sickle-cell Anemia Therapeutics market size is estimated to be worth US$ 1899.3 million in 2021 and is forecast to a readjusted size of USD 4857.3 million by 2028 with a CAGR of 14.4% during review period. Child accounting for % of the Sickle-cell Anemia Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Blood Transfusion segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Sickle-cell Anemia Therapeutics include Addmedica, Gamida Cell, GlycoMimetics, Pfizer, and Novartis, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Sickle-cell Anemia Therapeutics market is split by Type and by User. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by User. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Market segment by User, can be divided into
Child
Adult
Market segment by players, this report covers
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Sickle-cell Anemia Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Sickle-cell Anemia Therapeutics, with revenue, gross margin and global market share of Sickle-cell Anemia Therapeutics from 2019 to 2022.
Chapter 3, the Sickle-cell Anemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Sickle-cell Anemia Therapeutics market forecast, by regions, type and user, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Sickle-cell Anemia Therapeutics research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Sickle-cell Anemia Therapeutics
1.2 Classification of Sickle-cell Anemia Therapeutics by Type
1.2.1 Overview: Global Sickle-cell Anemia Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Sickle-cell Anemia Therapeutics Revenue Market Share by Type in 2021
1.2.3 Blood Transfusion
1.2.4 Pharmacotherapy
1.2.5 Bone Marrow Transplant
1.3 Global Sickle-cell Anemia Therapeutics Market by User
1.3.1 Overview: Global Sickle-cell Anemia Therapeutics Market Size by User: 2017 Versus 2021 Versus 2028
1.3.2 Child
1.3.3 Adult
1.4 Global Sickle-cell Anemia Therapeutics Market Size & Forecast
1.5 Global Sickle-cell Anemia Therapeutics Market Size and Forecast by Region
1.5.1 Global Sickle-cell Anemia Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Sickle-cell Anemia Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Sickle-cell Anemia Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Sickle-cell Anemia Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Sickle-cell Anemia Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Sickle-cell Anemia Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Sickle-cell Anemia Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Sickle-cell Anemia Therapeutics Market Drivers
1.6.2 Sickle-cell Anemia Therapeutics Market Restraints
1.6.3 Sickle-cell Anemia Therapeutics Trends Analysis
2 Company Profiles
2.1 Addmedica
2.1.1 Addmedica Details
2.1.2 Addmedica Major Business
2.1.3 Addmedica Sickle-cell Anemia Therapeutics Product and Solutions
2.1.4 Addmedica Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Addmedica Recent Developments and Future Plans
2.2 Gamida Cell
2.2.1 Gamida Cell Details
2.2.2 Gamida Cell Major Business
2.2.3 Gamida Cell Sickle-cell Anemia Therapeutics Product and Solutions
2.2.4 Gamida Cell Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Gamida Cell Recent Developments and Future Plans
2.3 GlycoMimetics
2.3.1 GlycoMimetics Details
2.3.2 GlycoMimetics Major Business
2.3.3 GlycoMimetics Sickle-cell Anemia Therapeutics Product and Solutions
2.3.4 GlycoMimetics Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 GlycoMimetics Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Sickle-cell Anemia Therapeutics Product and Solutions
2.4.4 Pfizer Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Sickle-cell Anemia Therapeutics Product and Solutions
2.5.4 Novartis Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Global Blood Therapeutics
2.6.1 Global Blood Therapeutics Details
2.6.2 Global Blood Therapeutics Major Business
2.6.3 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Product and Solutions
2.6.4 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Global Blood Therapeutics Recent Developments and Future Plans
2.7 Micelle BioPharma
2.7.1 Micelle BioPharma Details
2.7.2 Micelle BioPharma Major Business
2.7.3 Micelle BioPharma Sickle-cell Anemia Therapeutics Product and Solutions
2.7.4 Micelle BioPharma Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Micelle BioPharma Recent Developments and Future Plans
2.8 Bluebird Bio
2.8.1 Bluebird Bio Details
2.8.2 Bluebird Bio Major Business
2.8.3 Bluebird Bio Sickle-cell Anemia Therapeutics Product and Solutions
2.8.4 Bluebird Bio Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Bluebird Bio Recent Developments and Future Plans
2.9 Prolong Pharmaceuticals
2.9.1 Prolong Pharmaceuticals Details
2.9.2 Prolong Pharmaceuticals Major Business
2.9.3 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Product and Solutions
2.9.4 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Prolong Pharmaceuticals Recent Developments and Future Plans
2.10 Modus Therapeutics
2.10.1 Modus Therapeutics Details
2.10.2 Modus Therapeutics Major Business
2.10.3 Modus Therapeutics Sickle-cell Anemia Therapeutics Product and Solutions
2.10.4 Modus Therapeutics Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Modus Therapeutics Recent Developments and Future Plans
2.11 Sangamo Biosciences
2.11.1 Sangamo Biosciences Details
2.11.2 Sangamo Biosciences Major Business
2.11.3 Sangamo Biosciences Sickle-cell Anemia Therapeutics Product and Solutions
2.11.4 Sangamo Biosciences Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Sangamo Biosciences Recent Developments and Future Plans
2.12 Bioverativ
2.12.1 Bioverativ Details
2.12.2 Bioverativ Major Business
2.12.3 Bioverativ Sickle-cell Anemia Therapeutics Product and Solutions
2.12.4 Bioverativ Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Bioverativ Recent Developments and Future Plans
2.13 Imara
2.13.1 Imara Details
2.13.2 Imara Major Business
2.13.3 Imara Sickle-cell Anemia Therapeutics Product and Solutions
2.13.4 Imara Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Imara Recent Developments and Future Plans
2.14 Ironwood Pharmaceuticals
2.14.1 Ironwood Pharmaceuticals Details
2.14.2 Ironwood Pharmaceuticals Major Business
2.14.3 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Product and Solutions
2.14.4 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Ironwood Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Sickle-cell Anemia Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Sickle-cell Anemia Therapeutics Players Market Share in 2021
3.2.2 Top 10 Sickle-cell Anemia Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Sickle-cell Anemia Therapeutics Players Head Office, Products and Services Provided
3.4 Sickle-cell Anemia Therapeutics Mergers & Acquisitions
3.5 Sickle-cell Anemia Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Sickle-cell Anemia Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Sickle-cell Anemia Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by User
5.1 Global Sickle-cell Anemia Therapeutics Revenue Market Share by User (2017-2022)
5.2 Global Sickle-cell Anemia Therapeutics Market Forecast by User (2023-2028)
6 North America by Country, by Type, and by User
6.1 North America Sickle-cell Anemia Therapeutics Revenue by Type (2017-2028)
6.2 North America Sickle-cell Anemia Therapeutics Revenue by User (2017-2028)
6.3 North America Sickle-cell Anemia Therapeutics Market Size by Country
6.3.1 North America Sickle-cell Anemia Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by User
7.1 Europe Sickle-cell Anemia Therapeutics Revenue by Type (2017-2028)
7.2 Europe Sickle-cell Anemia Therapeutics Revenue by User (2017-2028)
7.3 Europe Sickle-cell Anemia Therapeutics Market Size by Country
7.3.1 Europe Sickle-cell Anemia Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by User
8.1 Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by User (2017-2028)
8.3 Asia-Pacific Sickle-cell Anemia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Region (2017-2028)
8.3.2 China Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by User
9.1 South America Sickle-cell Anemia Therapeutics Revenue by Type (2017-2028)
9.2 South America Sickle-cell Anemia Therapeutics Revenue by User (2017-2028)
9.3 South America Sickle-cell Anemia Therapeutics Market Size by Country
9.3.1 South America Sickle-cell Anemia Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by User
10.1 Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by User (2017-2028)
10.3 Middle East & Africa Sickle-cell Anemia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Sickle-cell Anemia Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Sickle-cell Anemia Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Sickle-cell Anemia Therapeutics Revenue by User, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Sickle-cell Anemia Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Sickle-cell Anemia Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Addmedica Corporate Information, Head Office, and Major Competitors
Table 7. Addmedica Major Business
Table 8. Addmedica Sickle-cell Anemia Therapeutics Product and Solutions
Table 9. Addmedica Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Gamida Cell Corporate Information, Head Office, and Major Competitors
Table 11. Gamida Cell Major Business
Table 12. Gamida Cell Sickle-cell Anemia Therapeutics Product and Solutions
Table 13. Gamida Cell Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. GlycoMimetics Corporate Information, Head Office, and Major Competitors
Table 15. GlycoMimetics Major Business
Table 16. GlycoMimetics Sickle-cell Anemia Therapeutics Product and Solutions
Table 17. GlycoMimetics Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Sickle-cell Anemia Therapeutics Product and Solutions
Table 21. Pfizer Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Novartis Corporate Information, Head Office, and Major Competitors
Table 23. Novartis Major Business
Table 24. Novartis Sickle-cell Anemia Therapeutics Product and Solutions
Table 25. Novartis Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Global Blood Therapeutics Corporate Information, Head Office, and Major Competitors
Table 27. Global Blood Therapeutics Major Business
Table 28. Global Blood Therapeutics Sickle-cell Anemia Therapeutics Product and Solutions
Table 29. Global Blood Therapeutics Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Micelle BioPharma Corporate Information, Head Office, and Major Competitors
Table 31. Micelle BioPharma Major Business
Table 32. Micelle BioPharma Sickle-cell Anemia Therapeutics Product and Solutions
Table 33. Micelle BioPharma Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Bluebird Bio Corporate Information, Head Office, and Major Competitors
Table 35. Bluebird Bio Major Business
Table 36. Bluebird Bio Sickle-cell Anemia Therapeutics Product and Solutions
Table 37. Bluebird Bio Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Prolong Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. Prolong Pharmaceuticals Major Business
Table 40. Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Product and Solutions
Table 41. Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Modus Therapeutics Corporate Information, Head Office, and Major Competitors
Table 43. Modus Therapeutics Major Business
Table 44. Modus Therapeutics Sickle-cell Anemia Therapeutics Product and Solutions
Table 45. Modus Therapeutics Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Sangamo Biosciences Corporate Information, Head Office, and Major Competitors
Table 47. Sangamo Biosciences Major Business
Table 48. Sangamo Biosciences Sickle-cell Anemia Therapeutics Product and Solutions
Table 49. Sangamo Biosciences Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Bioverativ Corporate Information, Head Office, and Major Competitors
Table 51. Bioverativ Major Business
Table 52. Bioverativ Sickle-cell Anemia Therapeutics Product and Solutions
Table 53. Bioverativ Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Imara Corporate Information, Head Office, and Major Competitors
Table 55. Imara Major Business
Table 56. Imara Sickle-cell Anemia Therapeutics Product and Solutions
Table 57. Imara Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Ironwood Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 59. Ironwood Pharmaceuticals Major Business
Table 60. Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Product and Solutions
Table 61. Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Global Sickle-cell Anemia Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 63. Global Sickle-cell Anemia Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 64. Breakdown of Sickle-cell Anemia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Sickle-cell Anemia Therapeutics Players Head Office, Products and Services Provided
Table 66. Sickle-cell Anemia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 67. Sickle-cell Anemia Therapeutics New Entrants and Expansion Plans
Table 68. Global Sickle-cell Anemia Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 69. Global Sickle-cell Anemia Therapeutics Revenue Share by Type (2017-2022)
Table 70. Global Sickle-cell Anemia Therapeutics Revenue Forecast by Type (2023-2028)
Table 71. Global Sickle-cell Anemia Therapeutics Revenue by User (2017-2022)
Table 72. Global Sickle-cell Anemia Therapeutics Revenue Forecast by User (2023-2028)
Table 73. North America Sickle-cell Anemia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 74. North America Sickle-cell Anemia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 75. North America Sickle-cell Anemia Therapeutics Revenue by User (2017-2022) & (USD Million)
Table 76. North America Sickle-cell Anemia Therapeutics Revenue by User (2023-2028) & (USD Million)
Table 77. North America Sickle-cell Anemia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 78. North America Sickle-cell Anemia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 79. Europe Sickle-cell Anemia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 80. Europe Sickle-cell Anemia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 81. Europe Sickle-cell Anemia Therapeutics Revenue by User (2017-2022) & (USD Million)
Table 82. Europe Sickle-cell Anemia Therapeutics Revenue by User (2023-2028) & (USD Million)
Table 83. Europe Sickle-cell Anemia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 84. Europe Sickle-cell Anemia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 85. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 86. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 87. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by User (2017-2022) & (USD Million)
Table 88. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by User (2023-2028) & (USD Million)
Table 89. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 90. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 91. South America Sickle-cell Anemia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 92. South America Sickle-cell Anemia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 93. South America Sickle-cell Anemia Therapeutics Revenue by User (2017-2022) & (USD Million)
Table 94. South America Sickle-cell Anemia Therapeutics Revenue by User (2023-2028) & (USD Million)
Table 95. South America Sickle-cell Anemia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 96. South America Sickle-cell Anemia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 97. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 98. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 99. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by User (2017-2022) & (USD Million)
Table 100. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by User (2023-2028) & (USD Million)
Table 101. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 102. Middle East & Africa Sickle-cell Anemia Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Sickle-cell Anemia Therapeutics Picture
Figure 2. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Type in 2021
Figure 3. Blood Transfusion
Figure 4. Pharmacotherapy
Figure 5. Bone Marrow Transplant
Figure 6. Sickle-cell Anemia Therapeutics Revenue Market Share by User in 2021
Figure 7. Child Picture
Figure 8. Adult Picture
Figure 9. Global Sickle-cell Anemia Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Sickle-cell Anemia Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Region (2017-2028)
Figure 12. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Region in 2021
Figure 13. North America Sickle-cell Anemia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Sickle-cell Anemia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Sickle-cell Anemia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Sickle-cell Anemia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Sickle-cell Anemia Therapeutics Market Drivers
Figure 19. Sickle-cell Anemia Therapeutics Market Restraints
Figure 20. Sickle-cell Anemia Therapeutics Market Trends
Figure 21. Addmedica Recent Developments and Future Plans
Figure 22. Gamida Cell Recent Developments and Future Plans
Figure 23. GlycoMimetics Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Novartis Recent Developments and Future Plans
Figure 26. Global Blood Therapeutics Recent Developments and Future Plans
Figure 27. Micelle BioPharma Recent Developments and Future Plans
Figure 28. Bluebird Bio Recent Developments and Future Plans
Figure 29. Prolong Pharmaceuticals Recent Developments and Future Plans
Figure 30. Modus Therapeutics Recent Developments and Future Plans
Figure 31. Sangamo Biosciences Recent Developments and Future Plans
Figure 32. Bioverativ Recent Developments and Future Plans
Figure 33. Imara Recent Developments and Future Plans
Figure 34. Ironwood Pharmaceuticals Recent Developments and Future Plans
Figure 35. Global Sickle-cell Anemia Therapeutics Revenue Share by Players in 2021
Figure 36. Sickle-cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Sickle-cell Anemia Therapeutics Revenue Market Share in 2021
Figure 38. Global Top 10 Players Sickle-cell Anemia Therapeutics Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Sickle-cell Anemia Therapeutics Revenue Share by Type in 2021
Figure 41. Global Sickle-cell Anemia Therapeutics Market Share Forecast by Type (2023-2028)
Figure 42. Global Sickle-cell Anemia Therapeutics Revenue Share by User in 2021
Figure 43. Global Sickle-cell Anemia Therapeutics Market Share Forecast by User (2023-2028)
Figure 44. North America Sickle-cell Anemia Therapeutics Sales Market Share by Type (2017-2028)
Figure 45. North America Sickle-cell Anemia Therapeutics Sales Market Share by User (2017-2028)
Figure 46. North America Sickle-cell Anemia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 47. United States Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Sickle-cell Anemia Therapeutics Sales Market Share by Type (2017-2028)
Figure 51. Europe Sickle-cell Anemia Therapeutics Sales Market Share by User (2017-2028)
Figure 52. Europe Sickle-cell Anemia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 53. Germany Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Sickle-cell Anemia Therapeutics Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Sickle-cell Anemia Therapeutics Sales Market Share by User (2017-2028)
Figure 60. Asia-Pacific Sickle-cell Anemia Therapeutics Revenue Market Share by Region (2017-2028)
Figure 61. China Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Sickle-cell Anemia Therapeutics Sales Market Share by Type (2017-2028)
Figure 68. South America Sickle-cell Anemia Therapeutics Sales Market Share by User (2017-2028)
Figure 69. South America Sickle-cell Anemia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Sickle-cell Anemia Therapeutics Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Sickle-cell Anemia Therapeutics Sales Market Share by User (2017-2028)
Figure 74. Middle East and Africa Sickle-cell Anemia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Sickle-cell Anemia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
